Your browser is no longer supported. Please, upgrade your browser.
BIO Bio-Rad Laboratories, Inc. monthly Stock Chart
BIO [NYSE]
Bio-Rad Laboratories, Inc.
IndexS&P 500 P/E4.58 EPS (ttm)116.78 Insider Own1.80% Shs Outstand29.72M Perf Week-6.84%
Market Cap16.19B Forward P/E47.83 EPS next Y11.19 Insider Trans-3.19% Shs Float21.37M Perf Month-4.36%
Income3.52B PEG0.26 EPS next Q3.30 Inst Own79.10% Short Float1.94% Perf Quarter7.26%
Sales2.38B P/S6.80 EPS this Y456.30% Inst Trans0.11% Short Ratio2.38 Perf Half Y8.66%
Book/sh296.93 P/B1.80 EPS next Y14.03% ROA36.30% Target Price643.75 Perf Year43.44%
Cash/sh38.16 P/C14.02 EPS next 5Y17.80% ROE49.90% 52W Range309.38 - 648.39 Perf YTD44.60%
Dividend- P/FCF43.85 EPS past 5Y80.40% ROI-4.50% 52W High-17.48% Beta0.89
Dividend %- Quick Ratio1.70 Sales past 5Y1.20% Gross Margin55.20% 52W Low72.95% ATR21.08
Employees8120 Current Ratio2.40 Sales Q/Q15.50% Oper. Margin12.50% RSI (14)41.54 Volatility4.12% 3.84%
OptionableYes Debt/Eq0.05 EPS Q/Q603.00% Profit Margin- Rel Volume1.58 Prev Close523.23
ShortableYes LT Debt/Eq0.00 EarningsOct 29 AMC Payout0.00% Avg Volume174.10K Price535.07
Recom1.50 SMA20-8.37% SMA50-4.18% SMA20012.67% Volume274,306 Change2.26%
Jan-08-20Initiated Wells Fargo Overweight $430
Jan-07-20Initiated Citigroup Buy $450
Oct-17-18Initiated Goldman Buy $350
Sep-20-18Initiated Morgan Stanley Equal-Weight $335
Feb-16-18Downgrade CL King Buy → Neutral
Jul-13-17Initiated Wells Fargo Outperform
Jun-28-17Upgrade Deutsche Bank Hold → Buy $220 → $255
Jan-18-17Initiated Deutsche Bank Hold $195
Oct-13-16Initiated CL King Buy
May-06-15Reiterated Jefferies Buy $150 → $165
Dec-18-09Initiated Maxim Group Buy $125
Nov-06-09Initiated Jefferies & Co Buy $130
Jul-17-09Initiated Soleil Buy $91
Sep-26-07Initiated Banc of America Sec Buy $110
Feb-23-07Downgrade Robert W. Baird Outperform → Neutral $83 → $76
Nov-27-20 09:21AM  
Nov-19-20 01:03PM  
11:30AM  
Nov-13-20 09:08AM  
Nov-11-20 12:19PM  
Nov-09-20 10:39AM  
Nov-04-20 12:20PM  
Oct-30-20 10:45AM  
04:31AM  
Oct-29-20 05:45PM  
04:59PM  
04:15PM  
Oct-28-20 04:36PM  
12:41PM  
09:53AM  
Oct-26-20 12:25PM  
Oct-24-20 08:35AM  
Oct-23-20 08:44AM  
Oct-22-20 12:33PM  
Oct-19-20 08:30AM  
Oct-12-20 02:53PM  
09:53AM  
Sep-25-20 01:52PM  
Sep-21-20 09:56AM  
Sep-14-20 09:46AM  
Sep-02-20 07:47AM  
Aug-31-20 12:54PM  
Aug-29-20 11:31AM  
Aug-24-20 11:35AM  
Aug-17-20 11:46AM  
Aug-10-20 08:31AM  
Aug-07-20 12:20PM  
10:23AM  
Aug-04-20 08:30AM  
Jul-31-20 08:33PM  
10:36AM  
Jul-30-20 05:45PM  
04:15PM  
Jul-29-20 09:16AM  
Jul-27-20 08:29AM  
Jul-24-20 07:31PM  
Jul-23-20 12:32PM  
Jul-15-20 08:01PM  
Jul-13-20 08:12PM  
Jul-09-20 03:57PM  
09:32AM  
Jun-30-20 05:18PM  
10:40AM  
Jun-15-20 11:31AM  
Jun-12-20 06:18PM  
Jun-11-20 07:30PM  
06:00AM  
Jun-08-20 10:22AM  
Jun-05-20 10:00AM  
Jun-01-20 09:07AM  
May-15-20 03:06PM  
May-13-20 03:34PM  
May-12-20 11:51AM  
May-07-20 06:06PM  
10:11AM  
May-06-20 08:25PM  
04:15PM  
May-05-20 08:00AM  
May-04-20 07:27PM  
11:12AM  
May-03-20 03:37PM  
Apr-30-20 04:51PM  
09:00AM  
Apr-29-20 12:34PM  
Apr-27-20 08:00AM  
06:16AM  
Apr-23-20 06:44PM  
Apr-22-20 04:25PM  
Apr-21-20 10:35AM  
08:30AM  
Apr-09-20 09:35AM  
09:23AM  
08:30AM  
Apr-08-20 10:34AM  
06:57AM  
Apr-07-20 08:30AM  
Apr-06-20 01:55PM  
Apr-02-20 09:42AM  
Mar-31-20 08:00AM  
Mar-23-20 06:16PM  
11:16AM  
Mar-20-20 10:43AM  
07:00AM  
Mar-19-20 05:30PM  
07:37AM  
Mar-18-20 07:24PM  
Mar-17-20 11:27AM  
Mar-14-20 11:30AM  
Mar-13-20 09:45AM  
Mar-12-20 07:30PM  
Mar-09-20 01:30PM  
08:34AM  
Feb-25-20 04:15PM  
Feb-24-20 05:47PM  
Feb-18-20 06:31PM  
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TUMOLO ANNETTEExecutive Vice PresidentNov 06Option Exercise159.321,200191,1845,322Nov 10 12:40 PM
TUMOLO ANNETTEExecutive Vice PresidentNov 06Sale640.721,200768,8654,122Nov 10 12:40 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 11Option Exercise0.003,2000299,834Sep 15 02:13 PM
HUTTON RONALD WVice President and TreasurerSep 11Option Exercise0.0015004,740Sep 14 06:59 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 11Option Exercise0.0060004,420Sep 14 06:55 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 11Option Exercise0.0060004,341Sep 14 06:50 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 11Option Exercise69.781,00069,78022,743Sep 14 11:42 AM
Magni GiovanniEVP, Chief Strategy OfficerSep 10Option Exercise259.111,771458,88222,410Sep 14 11:42 AM
Magni GiovanniEVP, Chief Strategy OfficerSep 08Option Exercise0.00400021,829Sep 09 01:48 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 07Option Exercise0.003,0000298,122Sep 09 02:53 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 07Option Exercise0.0050001,960Sep 09 02:00 PM
HUTTON RONALD WVice President and TreasurerSep 07Option Exercise0.0017004,649Sep 09 01:57 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 07Option Exercise0.0060004,039Sep 09 01:56 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 07Option Exercise0.0060004,118Sep 09 01:44 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 05Option Exercise0.002,6000420,261Sep 09 02:53 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 05Option Exercise0.0050001,633Sep 09 02:00 PM
HUTTON RONALD WVice President and TreasurerSep 05Option Exercise0.0018004,542Sep 09 01:57 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 05Option Exercise0.0060003,665Sep 09 01:56 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 05Option Exercise0.00500021,677Sep 09 01:46 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 05Option Exercise0.0060003,765Sep 09 01:44 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 04Option Exercise0.002,6000418,951Sep 09 02:53 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 04Option Exercise0.0050001,306Sep 09 02:00 PM
HUTTON RONALD WVice President and TreasurerSep 04Option Exercise0.0018004,425Sep 09 01:57 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 04Option Exercise0.0060003,273Sep 09 01:56 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 04Option Exercise0.00500021,425Sep 09 01:46 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 04Option Exercise0.0060003,373Sep 09 01:44 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 03Option Exercise0.0055602,966Sep 08 01:00 PM
Magni GiovanniEVP, Chief Strategy OfficerSep 03Option Exercise0.00371021,109Sep 08 12:51 PM
SCHWARTZ NORMAN DChairman, President and CEOSep 03Option Exercise0.002,3190417,501Sep 08 03:20 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 03Option Exercise0.004640967Sep 08 01:09 PM
HUTTON RONALD WVice President and TreasurerSep 03Option Exercise0.0015404,299Sep 08 12:43 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 03Option Exercise0.0055602,866Sep 08 12:32 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 19Option Exercise121.5921,1502,571,56433,585Aug 21 02:01 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 19Sale519.8812,8476,678,84420,738Aug 21 02:01 PM
Magni GiovanniEVP, Chief Strategy OfficerAug 18Sale518.812,3821,235,80512,435Aug 19 12:42 PM
SCHWARTZ NORMAN DChairman, President, and CEOJun 12Option Exercise84.5737,0003,129,090316,982Jun 15 07:02 PM
Crowley MichaelEVP, GBL Commercial OperationsJun 01Sale485.401,500728,1002,310Jun 02 05:11 PM
HUTTON RONALD WVice President and TreasurerMay 13Sale457.35443202,6064,140May 14 01:11 PM
Last Andrew J.EVP, Chief Operating OfficerApr 29Option Exercise0.001,00001,026Apr 30 02:14 PM
Daskal IlanEVP, Chief Financial OfficerApr 08Option Exercise0.007000700Apr 09 01:07 PM
ERNST TIMOTHY SEVP, General Counsel & SecDec 04Option Exercise159.321,250199,1502,362Dec 05 07:03 PM
ERNST TIMOTHY SEVP, General Counsel & SecDec 04Sale370.111,906705,436456Dec 05 07:03 PM